Cargando…

Preclinical data on co-delivery of temozolomide and talazoparib by fucodain-coated nanoscale metal organic frameworks for colorectal cancer chemoradiation

Nanoparticle characterization and in vitro data on the effects of combined PARP inhibition and DNA damage by chemoradiation are shown. This data accompanies the research article “Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	DuRoss, Allison N., Landry, Madeleine R., Thomas, Charles R., Neufeld, Megan J., Sun, Conroy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Data Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488234/ https://www.ncbi.nlm.nih.gov/pubmed/34632011 http://dx.doi.org/10.1016/j.dib.2021.107394

Ejemplares similares

Development of a Pemetrexed/Folic Acid Nanoformulation: Synthesis, Characterization, and Efficacy in a Murine Colorectal Cancer Model
por: Rosch, Justin G., et al.
Publicado: (2020)

Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics
por: Rosch, Justin G., et al.
Publicado: (2020)

Development of a G2/M arrest high-throughput screening method identifies potent radiosensitizers
por: Landry, Madeleine, et al.
Publicado: (2022)

PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma
por: Del Pozo, Vanessa, et al.
Publicado: (2021)

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019)

Nanoalginates via Inverse-Micelle Synthesis: Doxorubicin-Encapsulation and Breast Cancer Cytotoxicity
por: Rosch, Justin G., et al.
Publicado: (2018)

Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
por: Faustino, Alexandre Ciuffi, et al.
Publicado: (2020)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy
por: Landry, M.R., et al.
Publicado: (2020)

Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors
por: Mallick, Supriya, et al.
Publicado: (2015)

Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems †
por: Petrenko, Daria, et al.
Publicado: (2022)

ACT-10 TREATMENT FOR GLIOBLASTOMA RECURRED AFTER CONCOMITANT CHEMORADIATION THERAPY WITH TEMOZOLOMIDE AND THEIR PROGNOSIS
por: Mori, Kanji, et al.
Publicado: (2019)

Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
por: Ly, K. Ina, et al.
Publicado: (2018)

Biodistribution and Toxicity of Micellar Platinum Nanoparticles in Mice via Intravenous Administration
por: Brown, Anna L., et al.
Publicado: (2018)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models
por: Davy, Mélodie, et al.
Publicado: (2023)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
por: Ly, K. Ina, et al.
Publicado: (2019)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

A Phase I trial of talazoparib in patients with advanced hematologic malignancies
por: Gopal, Ajay K, et al.
Publicado: (2021)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Data on the interaction of hyperaccumulating plants with nanoscale metals Zn and Cd
por: Imperiale, Davide, et al.
Publicado: (2022)

XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA
por: Hirota, Kouji, et al.
Publicado: (2022)

Recurrence of herpes simplex encephalitis associated with temozolomide chemoradiation for malignant glioma: a case report and review of the literature
por: Christman, Mitalee P., et al.
Publicado: (2014)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors
por: Durairaj, Chandrasekar, et al.
Publicado: (2021)

Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
por: Schwarz, Florian, et al.
Publicado: (2022)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

Scrutinizing the datasets obtained from nanoscale features of spider silk fibres
por: Silva, Luciano P, et al.
Publicado: (2014)

Electron microscopy dataset for the recognition of nanoscale ordering effects and location of nanoparticles
por: Boiko, Daniil A., et al.
Publicado: (2020)

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
por: Belz, Jodi E., et al.
Publicado: (2017)

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
por: Hoffman, Justin, et al.
Publicado: (2019)

Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2021)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment
por: Guo, Cen, et al.
Publicado: (2022)

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors
por: Luo, Yang, et al.
Publicado: (2023)

Mathematical description data: Spin-resolved electron transport in nanoscale heterojunctions: Theory and applications
por: Useinov, Artur, et al.
Publicado: (2020)

Tribocorrosion Behavior of Micro/Nanoscale Surface Coatings
por: Hoque, Md Ashraful, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h82ravhh99tddbfjgl663hun18